注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Viracta Therapeutics Inc是一家临床阶段的精准肿瘤学公司。该公司专注于开发治疗病毒相关恶性肿瘤的新药。该公司正在对其作为治疗复发/难治性Epstein-Barr病毒阳性(EBV+)淋巴瘤疗法的组合候选产品进行临床试验。其主要候选产品是其研究药物nanatinostat和抗病毒药物valganciclovir(统称为 Nana-val)的全口服联合疗法。Nana-val正在多项正在进行的临床试验中进行评估,包括用于治疗多种复发/难治性EBV+淋巴瘤(NAVAL-1)亚型的II期一揽子试验,以及用于治疗EBV+复发和其他EBV+实体瘤的Ib/II期试验。该公司的候选产品还包括临床阶段非共价ITK/BTK抑制剂vecabrutinib和临床前阶段PDK-1抑制剂VRx-510。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Ivor Royston | 78 | 2007 | Director |
Thomas Eric Darcy | 73 | 2021 | Independent Director |
Stephen Rubino | 66 | 2021 | Independent Director |
Barry J. Simon | 59 | 2021 | Independent Director |
Mark Andrew Rothera | 61 | 2022 | CEO, President & Director |
Roger James Pomerantz | 67 | 2020 | Independent Chairman of the Board |
Robert Baiocchi | - | 2018 | Member of Scientific Advisory Board |
Ronald Levy | - | 2018 | Member of Scientific Advisory Board |
Jane F. Barlow | 63 | 2021 | Independent Director |
Daniel Douglas Von Hoff | 76 | - | Member of Scientific Advisory Board |
Lawrence S. Young | - | 2018 | Member of Scientific Advisory Board |
Pierluigi Porcu | - | 2018 | Member of Scientific Advisory Board |
Flavia Borellini | 65 | 2021 | Independent Director |
Samuel Lafayette Murphy | 46 | 2019 | Independent Director |
Carl H. June | 70 | 2018 | Member of Scientific Advisory Board |
Gavin Giovannoni | - | 2024 | Member of Scientific Advisory Board |
Shannon Kenney | - | - | Member of Scientific Advisory Board |
Jane Chung | 52 | 2022 | Independent Director |
Douglas V. Faller | - | - | Scientific Founder & Chairman of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核